JNJJohnson & Johnson

$270.09

$167.3552 weeks$273.40

Price

$270.09+62%1Y

1M+4.1%1Y+62%

Prices are end-of-day closes. This is a research view, the focus is on the fundamentals, quality and valuation below, not intraday price.

Smart Score

Top tier

9/10

Value50

Quality91

Momentum68

Growth55

Strongest Quality, weakest Value · ranked vs Healthcare peers. The five questions below judge the company on its own terms.

What they do

Johnson & Johnson and its subsidiaries (the Company) have approximately 138,200 employees worldwide engaged in the research and development, manufacture and sale of a broad range of products in the healthcare field. Johnson & Johnson is a holding company, with operating companies conducting business in virtually all countries of the world. The Company’s primary focus is products related to human health and well-being.

In the company’s own words · 10-K filed Feb 11, 2026 · SEC EDGAR

P/E (TTM)31.3

Market Cap$549.78B

1Y Return+62%

5Y Return+81%

Business segments

Q2 2026 · $13.00B

The company’s own SEC segment disclosure.

DARZALEX$2.44B19%
Tremfya$1.47B11%
INVEGASUSTENNAXEPLIONTRINZATREVICTA$738.0M6%
Xarelto$664.0M5%
GENERAL$596.0M5%
TRAUMA$536.0M4%
Other (27)$6.57B51%

Johnson & Johnson (JNJ) reported revenue of $25.3B in Q2 2026 (quarter ended June 28, 2026), up 6.6% from the same quarter a year earlier. That came with a gross margin of 68% and net income of $5.53B (22% of revenue). For the full year FY2025, revenue was $94.2B (+6.0% year on year) and net income $26.8B. Its largest product in 2026-Q2 was DARZALEX at $2.44B, 19% of the disclosed total, just ahead of Tremfya at 11%.

Raw charts

11 series · TTM

As reported to the SEC, without any scoring.

Drug Manufacturers - General

Ranks #2 of 16 by Smart Score